Vanguard Amends Regeneron Stake: Holds 7.6% as of Dec 29, 2023

TL;DR

**Vanguard still owns 7.6% of Regeneron, showing continued institutional confidence.**

AI Summary

The Vanguard Group, a major investment firm, filed an amendment to its Schedule 13G on February 13, 2024, disclosing its ownership in Regeneron Pharmaceuticals Inc. As of December 29, 2023, Vanguard reported beneficial ownership of 8,502,745 shares of Regeneron's Common Stock, representing 7.6% of the company's outstanding shares. This filing indicates Vanguard's continued significant, but passive, investment in Regeneron, which is important for investors as large institutional holdings can provide stability and signal confidence in the company's long-term prospects.

Why It Matters

This filing shows that a major institutional investor, Vanguard, maintains a substantial stake in Regeneron, which can influence stock stability and investor confidence.

Risk Assessment

Risk Level: low — This is a routine update from a passive institutional investor, indicating no immediate change in company control or strategy.

Analyst Insight

Investors should note Vanguard's continued significant, but passive, stake in Regeneron, which suggests long-term institutional confidence without indicating any immediate strategic changes or activist intent.

Key Numbers

• 8,502,745 — Shares Beneficially Owned (Represents the total number of Regeneron shares Vanguard holds, indicating a significant investment.)
• 7.6% — Percentage of Class (Shows Vanguard's substantial ownership stake in Regeneron, making them a key institutional holder.)
• December 29, 2023 — Date of Event (The snapshot date for the reported ownership, providing a clear reference point for the disclosed stake.)

Key Players & Entities

• The Vanguard Group (company) — the reporting person and institutional investor
• Regeneron Pharmaceuticals Inc (company) — the subject company whose securities are being reported
• 8,502,745 (dollar_amount) — number of shares beneficially owned by Vanguard
• 7.6% (dollar_amount) — percentage of Regeneron's class of securities beneficially owned by Vanguard
• December 29, 2023 (date) — the date of the event requiring the filing
• February 13, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Vanguard will maintain a significant, passive stake in Regeneron Pharmaceuticals Inc. (The Vanguard Group) — high confidence, target: Next 12 months

FAQ

From the Filing

0001104659-24-021814.txt : 20240213 0001104659-24-021814.hdr.sgml : 20240213 20240213171222 ACCESSION NUMBER: 0001104659-24-021814 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41938 FILM NUMBER: 24629379 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: VANGUARD GROUP INC CENTRAL INDEX KEY: 0000102909 ORGANIZATION NAME: IRS NUMBER: 231945930 STATE OF INCORPORATION: PA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 BUSINESS PHONE: 6106691000 MAIL ADDRESS: STREET 1: PO BOX 2600 STREET 2: V26 CITY: VALLEY FORGE STATE: PA ZIP: 19482-2600 SC 13G/A 1 tv01800-regeneronpharmaceuti.htm SCHEDULE 13G/A regeneronpharmaceuticalsinc SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer:  Regeneron Pharmaceuticals Inc Title of Class of Securities:  Common Stock CUSIP Number:  75886F107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). (Continued on the following page(s))     13G CUSIP No.:  75886F107 1.  NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON The Vanguard Group - 23-1945930 2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP A.  B.  X 3.  SEC USE ONLY 4.  CITIZENSHIP OF PLACE OF ORGANIZATION Pennsylvania (For questions 5-8, report the number of shares beneficially owned by each reporting person with:) 5.  SOLE VOTING POWER 0 6.  SHARED VOTING POWER 132,744 7.  SOLE DISPOSITIVE POWER 8,390,875 8.  SHARED DISPOSITIVE POWER 447,365 9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 8,838,240 10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES N/A 11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 8.25% 12.  TYPE OF REPORTING PERSON IA     SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Act of 1934 Item 1(a) - Name of Issuer: Regeneron Pharmaceuticals Inc Item 1(b) - Address of Issuer's Principal Executive Offices: 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Item 2(a) - Name of Person Filing: The Vanguard Group - 23-1945930 Item 2(b) – Address of Principal Business Office or, if none, residence: 100 Vanguard Blvd. Malvern, PA 19355